Australia's largest stock trading and investment forum Australia's #1 stock forum

AN1

Click for more information

0.00%

0.8¢ anagenics limited

China deal..... Fukang Ren?, page-24

First 24 Last

Share
Profile

Follow
eieio

3,780 Posts.

64

06/05/18

13:24

Post #: 32913121
Share

Originally posted by Trae ↑

Hi bread

Appreciate you sharing your research.

I have just run a few searches on the Fù kāngrén (阜康仁) company and I have some questions regarding your research.

You've stated
"Self claming on frontal R&D research, which i couldnt find any detail about it."
With the understanding that the company is not listed, I would not expect to see their name published over the net regarding products that they distribute however the search below produces >5000 search results and every result I've checked appears relevant to the company:
https://www.google.com.au/search?q="阜康仁" -www.fukangren.com&newwindow=1&safe=off&rlz=1C1CHBF_en-GBAU713AU714&ei=oLftWsTLBMT_8QW5hLzQAg&start=10&sa=N&biw=1242&bih=579
Going back to 1999, these include products, hiring, partnering, government validations, projects, R&D hiring, R&D indications etc.

&
"Smaller cap than cellmid."
How did you draw conclusion on the companies market capitalisation given it is currently an unlisted company?

If you don't mind my asking, can you type/read chinese?
If yes, could you advise where I'm going wrong with my search?

-----------------

Below is a good write up I found on the development & R&D side of the business (from a chinese R&D job ad):
北京阜康仁生物制药科技有限公司

简介

公司概况
北京阜康仁生物制药科技有限公司是一家专业从事新药研发的创新型公司。公司于2000年创办，于2002年正式成立运作，总部坐落于北京丰台科技园区，因公司发展壮大2014年底公司搬迁至大兴区金星路30号。阜康仁多年来致力于创新药物的研究开发，积累了较丰富的经验和资源，在创新药物领域处于国内领先水平。2002年至今，公司连续被认证为“北京市高新技术企业”、“国家级高新技术企业”，并获得“北京国际企业孵化中心生物制药实验室”、“中关村科技园区专利引擎试点企业”、“北京丰台科技园区缓释制剂平台”等相关荣誉。

组织结构
阜康仁组织结构清晰，分工明确，设有合成部、制剂部和分析部三大重点实验科室，肩负新药研发的重任，另有信息部、专利部、审评部、市场部负责新药的调研、申报及推广等业务，还有其他部门负责公司科研以外的相关事务，整体上形成了一种非常严谨的新药研发的运行模式。

研发团队
目前阜康仁共有产品开发一线人员105人，研究生以上学历占60％以上，本科以上学历占90％以上，该团队能够在开发国家级三类新药及创新药物方面具有较丰富的经验，是国内研发行业内的一支技术先进团队。
为了更好的发展新药研发的事业，目前阜康仁已于多家国内知名的科研院校建立了密切的研发合作关系：如，与天津大学药学院建立了在生物制品、小分子化合物及药物分析上的密切合作，和清华大学化学系及化工系建立了就核苷类及多肽类药物开发的密切合作关系，另外阜康仁和首都医科大学、北大医学院、军事医学科学院等也建立了产学研合作关系，成立学生实习基地，进一步拓宽了公司的科研资源和对外合作。

科研设备
阜康仁的科研总面积近3000m2，各实验室均配备小试、中试设备，满足新药开发各阶段要求，分析中心配备进口液相色谱仪（HPLC）20台、气相色谱仪（GC）1台、原子吸收分光光度计1台、蒸发光散射检测仪1台、岛津示差检测仪1台、紫外分光光度计2台、旋光仪1台等大量科研设备，同时，我们和北京大学分析中心、首都医科大学等建立了广泛的业务合作关系，拓宽了科研资源。目前公司仍在积极的拓展公司的研发规模及资源，2010年，阜康仁新药合成基地在大兴区建立运营，该基地配有先进而全面的研发设备，保证了新药合成项目的顺利进行。
以下是公司实验室的概况
合成室：
制剂室：
分析室：

科研领域
阜康仁致力于国内外新药的开发，其涉及的业务领域包括如下几个方面
1、高难度的仿制药：具有一定的技术难度药物的仿制
2、非专利药物抢仿、高仿
3、国外在研及上市产品的引进
4、创新药物：有独立知识产权的仿创药
5、新制剂：缓释制剂技术，难容药物制剂及脂肪乳
6、合成工艺产业化承接
7、重大合成工艺项目技术改进
8、新建药厂、车间业务咨询
9、选题立项业务咨询
10、专利事务业务咨询

对外合作
国内合作
阜康仁在立足于独立创新的基础上也广泛和国内外研发单位及生产企业合作，形成了信息共享的技术创新平台，新的技术创新项目不断推出，为公司的高端技术研发提供了丰富的素材。目前阜康仁整合拓宽科研资源，已与国内多所知名院校和一百多个厂家建立了广泛深入的业务，与清华大学、天津大学药学院、北京大学、军事科学院等多个科研院校有长期的合作。其中，重点合作的院校有清华大学小分子实验室、肽类实验室、高分子实验室；天津大学药学院小分子实验室、生物制品实验室。
此外还与国内数百家知名制药企业有过合作，包括江中制药、仁和集团、济民可信、新华制药、信邦制药、诺金制药、宏奇制药、双成制药、四环科宝、普洛康裕、重庆科瑞、珠海联邦、梧州制药、石药集团、四川百利、上海信谊、珠海同益、广东邦民、圣济堂制药、王老吉制药、白云山制药、悦康、三精、步长、振东、尖峰、金陵、广药、马应龙等百家大型知名制药企业。
国际合作
要想做强制药，就要走国际化道路：师夷长技以制夷。公司非常重视国际合作，
以下是已经建立合作关系的国外院校及企业
IPI隶属于英国著名的University of Bradford，是英国及全欧洲最大的将人工智能和计算机模拟技术应用于新药开发的研究院之一。也是英国政府指定的工业合作中心。主要在缓释制剂及难溶药物方面经验丰富
阜康仁已与其达成若干协议，旨在共同开发高端制剂新技术
多伦多医药技术研究所（TIPT）是北美顶级制药教育、技术和研究机构。加拿大的所有制药执业上岗证都由该学院核发；因其在医药技术教育和培训方面以优秀、务实的精神而闻名于世。其缓释制剂技术经验丰富和产品进入欧美市场注册经验丰富
FITZROY PARTNERS LIMITED是一家致力于生命科学和生物工业的专业技术公司，致力于生物医药投资，为国内外投资者和合作伙伴提供生物医药技术咨询服务。该公司投资的系列产品已经在欧美进入临床研究，可以引进国内，在国内上市。其创始人ALAN是著名药物学家、金融家。
阜康仁与该公司在医药信息咨询和药品进口方面已建立了稳定的合作关系。
德国瀚辉（HH）公司致力于新型给药系统、新型包装模式、以及特殊制药设备的开发和生产。阜康仁已经与该公司达成协议，引进诸多先进的技术及设备

知识产权
北京市专利引擎单位
经过长时间的探索和沉淀，阜康仁实现了专利保护、新化合物研发、中药新药研发及新制剂技术的多元化发展。在知识产权保护方面，公司目前已拥有近600项有独立知识产权的品种，其中金多福韦已经申请了国际专利，还有10项待申请国际专利品种；在研发的项目中还有六十余项专利正在试验中，预计年底可以上报。目前公司已经近10项发明专利已经获得发明专利证书。10多项具有独立知识产权的1类创新新药已经进入新药申报阶段。

发展理念
阜康仁自创立之日起就奉行“精诚服务、科学创新”信念，积累了一批优秀的企业开拓者，团队精诚合作，勇于创新，公司全体员工都在为将公司发展成一个国际创新型的药物研究机构而共同努力奋斗。为国家制药行业的发展和民族用药水平的提高尽职尽责。争取早日摆脱仿制药的困惑，达到向创新药转化的质的飞跃。
阜康仁正在成长和发展中，相信我们会做的更好……!
北京阜康仁生物制药科技有限公司欢迎您的加入！！！

Beijing Ji Kangren Bio-pharmaceutical Technology Co., Ltd.

Brief

Corporate Profile
Beijing Ji Kangren Bio-pharmaceutical Technology Co., Ltd. is an innovative company specializing in the research and development of new drugs. The company was founded in 2000 and was formally established in 2002. The headquarters is located in Beijing Fengtai Science and Technology Park. Due to the company's development and growth at the end of 2014, the company moved to No. 30, Venus Road, Daxing District. Pei Kangren has been committed to the research and development of innovative drugs for many years and has accumulated rich experience and resources and is at the leading level in the field of innovative drugs. Since 2002, the company has been continuously certified as a "high-tech enterprise in Beijing" and a "national high-tech enterprise". It has also won the "Biopharmaceutical Laboratory of Beijing International Business Incubation Center", "Patented Engine Patent Pilot Enterprise in Zhongguancun Science Park," and " "Beijing Fengtai Science Park Sustained-release Formulation Platform" and other related honors.

Organization structure: The organization structure of
Kang Kangren is clear and the labor division is clear. There are three major experimental departments in the synthesis department, the preparation department, and the analysis department. They are responsible for the development of new drugs, and the information department, patent department, review department, and marketing department are responsible for new medicines. Research, reporting, and promotion services, among other departments, are responsible for company-related research and other related matters. As a whole, a very stringent new drug development model has been formed.

The research and development team
currently has a total of 105 frontline staff for product development, including more than 60% of postgraduates or above. Bachelor degree or above accounted for more than 90%. The team has extensive experience in the development of state-level Class III new drugs and innovative drugs. A technologically advanced team in the domestic R&D industry.
In order to better develop the cause of new drug research and development, Ji Kangren has established close R&D cooperation relationships with a number of well-known research institutes in China. For example, he has established analysis of biological products, small molecule compounds, and pharmaceuticals with the Tianjin University School of Pharmacy. The close cooperation between Tsinghua University and the Department of Chemistry and the Department of Chemical Engineering of Tsinghua University established a close cooperation relationship on the development of nucleosides and peptides. In addition, Ji Kangren and the Capital Medical University, Peking University Medical College, and the Academy of Military Medical Sciences have also established research institutes. Cooperation, the establishment of student practice bases, and further broaden the company's scientific research resources and foreign cooperation.

Research equipment
The total scientific research area of Ji Kangren is nearly 3,000 m2. Each laboratory is equipped with small-scale test and pilot-plant equipment to meet the requirements of each phase of new drug development. The analysis center is equipped with 20 imported liquid chromatographs (HPLC) and 1 gas chromatograph (GC). , atomic absorption spectrophotometer 1 set, evaporative light scattering detector 1 set, Shimadzu differential detector 1 set, UV spectrophotometer 2 sets, polarimeter 1 set and a large number of scientific research equipment, at the same time, we and the analysis center of Peking University, Capital Medical University established a wide range of business partnerships and expanded scientific research resources. At present, the company is still actively expanding the company's R&D scale and resources. In 2010, Fukangren New Drug Synthesis Base was established in Daxing District. The base is equipped with advanced and comprehensive R&D equipment to ensure the smooth progress of the new drug synthesis project.
The following is a summary of the company's laboratory
synthesis room:
Preparation room:
Analysis room:

Research field
Kang Kangren is committed to the development of new drugs at home and abroad, the business areas involved include the following aspects
1, a difficult generics: a certain technology Difficulties of drug imitation
2, non-patent drugs grab imitation, high imitation
3, foreign research and introduction of marketed products
4, innovative drugs: imitation drugs with independent intellectual property rights
5, new preparations: sustained-release preparation technology, difficult to drug Formulations and fat emulsions
6, industrialization of synthetic processes undertaken
7, technological improvement of major synthetic process projects
8, new business establishments, workshop business consultations
9, topic selection project business consultations
10, patent affairs business consulting and

foreign cooperation
domestic cooperation
On the basis of independent innovation, Ji Kangren also extensively collaborates with R&D units and manufacturing companies at home and abroad to form a technology innovation platform for information sharing. New technology innovation projects are continuously launched, providing rich materials for the company's high-end technology research and development. . Currently, Kang Kangren has broadened its research and development resources, and has established extensive and in-depth business with several well-known universities and more than one hundred manufacturers in China. There are several scientific research institutions such as Tsinghua University, Tianjin University School of Pharmacy, Peking University, and Military Academy of Sciences. long term partnership. Among them, the key cooperation institutions are Tsinghua University Small Molecular Laboratory, Peptide Laboratory, Polymer Laboratory; Tianjin University School of Pharmacy Small Molecular Laboratory, Biological Products Laboratory.
In addition, it has cooperated with hundreds of well-known domestic pharmaceutical companies, including Jiangzhong Pharmaceutical, Renhe Group, Jimin Credible, Xinhua Pharmaceutical, Xinbang Pharmaceutical, Nuojin Pharmaceutical, Hongqi Pharmaceutical, Shuangcheng Pharmaceutical, and Sihuan Kebao. , Procter & Gamble, Chongqing Corey, Zhuhai Federation, Luzhou Pharmaceutical, Shijiazhuang Group, Sichuan Baili, Shanghai Xinyi, Zhuhai Tongyi, Guangdong Bangmin, Shengjitang Pharmaceutical, Wanglaoji Pharmaceutical, Baiyunshan Pharmaceutical, Yuekang, Three well-known pharmaceutical companies such as Sanjing, Buchang, Zhendong, Jianfeng, Jinling, Guangyao, and Ma Yinglong.
If international cooperation wants to make compulsory drugs, we must take the path of internationalization. The company attaches great importance to international cooperation. The
following is the
IPI of foreign institutions and companies that have established a cooperative relationship. It is affiliated with the famous University of Bradford in the UK. It is the largest research institute in the UK and Europe that applies artificial intelligence and computer simulation technology to the development of new drugs. one. It is also an industrial cooperation center designated by the British government. Experienced mainly in sustained-release preparations and infusible medicines
Kang Kangren has reached several agreements with it to develop high-end formulation technologies. The
Toronto Institute of Pharmaceutical Technology (TIPT) is North America's top pharmaceutical education, technology and research institution. All of Canada's pharmaceutical industry licenses are issued by the college; they are known for their excellence and pragmatism in medical technology education and training. Its long-term release agent has rich experience in technology and experience in product registration in European and American markets.
FITZROY PARTNERS LIMITED is a professional technology company dedicated to the life sciences and bio-industry. It is committed to investing in bio-pharmaceuticals and provides bio-pharmaceutical technology consulting services to domestic and foreign investors and partners. The company's investment series have entered clinical research in Europe and the United States, can be introduced domestically, and listed in the country. Its founder ALAN is a famous pharmacologist and financier.
Pei Kangren has established a stable cooperative relationship with the company in medical information consultation and drug import.
The German company HH (HH) is committed to the development and production of new drug delivery systems, new packaging models, and special pharmaceutical equipment. Ren Fukang has reached an agreement with the company, the introduction of many advanced technology equipment and

intellectual property rights
in Beijing patented engine unit
after a long period of exploration and precipitation, Ren Fukang achieve patent protection, research and development of new compounds, new drug development and formulation technology of traditional Chinese medicine Diversified development. In terms of intellectual property protection, the company currently has nearly 600 varieties of intellectual property rights, of which Jin Duofuwei has applied for international patents, and there are 10 pending international patent varieties; there are still 60 in the research and development projects. The remaining patents are being tested and are expected to be reported by the end of the year. At present, the company has obtained nearly 10 invention patents and has obtained a patent for invention. More than 10 types of innovative new drugs with independent intellectual property rights have entered the new drug application stage.

Development Philosophy
Since its inception, Kang Kangren has been pursuing the faith of "sincere service and scientific innovation." It has accumulated a group of outstanding corporate pioneers, and the team has sincerely cooperated and dared to innovate. All employees of the company are developing the company into an international innovation. Type of drug research institutions and work hard together. We are responsible for the development of the national pharmaceutical industry and the improvement of the national drug use. Try to get rid of the confusion of generic drugs as soon as possible and achieve a qualitative leap in the transformation of innovative drugs.
Kang Kangren is growing and developing, I believe we will do better......!
Beijing Ji Kangren Biopharmaceutical Technology Co., Ltd. welcomes you to join! ! !

Expand

I've had a quick look at some of their "patents" Not impressed. Somebody tell me.... Why do we have to get into bed right now with a company that "patents" concoctions consisting of Chinese traditional medicinal ingredients combined with pharmaceuticals developed in the West. Where is the "science" in that?

Last edited by eieio: 06/05/18

CDY Price at posting: 53.0¢ Sentiment: Hold Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

CRI

Critica unveils fresh REE hits near Jupiter play in WA – and 5 new prospects

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

THB

Thunderbird picks up plethora of uranium targets based on EM survey in Canada

NSM

North Stawell Minerals set to raise $1.3M in capital raising for exploration in Victoria

SGR

Thousands eye Star on HotCopper, SkyCity in strife – are ASX casino stocks safe anymore?

There are more pages in this discussion • 26 more messages in this thread...

First 24 Last

Add AN1 (ASX) to my watchlist

SPONSORED BY